RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Revenue

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$108.9B
P/E ratio
SummaryFinancials
Period EndRevenue (Million USD)YoY (%)
Dec 31, 202411,020+11.66%
Dec 31, 20239,869+10.51%
Dec 31, 20228,931+17.91%
Dec 31, 20217,574+22.06%
Dec 31, 20206,206+49.07%
Dec 31, 20194,163+36.59%
Dec 31, 20183,048+22.46%
Dec 31, 20172,489+46.20%
Dec 31, 20161,702+64.89%
Dec 31, 20151,032+77.86%
Dec 31, 2014580-52.11%
Dec 31, 20131,212-20.63%
Dec 31, 20121,527+8.25%
Dec 31, 20111,411+883.91%
Dec 31, 2010143

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)